Ketogenic Therapy Decision Algorithm for Cancer Patients (2026)

Ketogenic Therapy Decision Algorithm

PATIENT CONSIDERED FOR KETOGENIC THERAPY

↓

Step 1: Anatomic & Tissue Risk Screening

Small Intestine / FAP

• High mucosal lipid exposure
• Primary small bowel tumors
• Outcome: HIGH FAO RISK ➔ Direct to Alternative Protocol

All Other Primary Sites

• CNS, Colon, Lung, Head & Neck, Breast, Prostate
• Outcome: Low immediate mucosal risk ➔ Proceed to Step 2

↓

Step 2: Genomic & Pathway Profiling

High FAO Vulnerability

• APC mutation / loss
• CPT1A overexpression
• Upregulated PPARα/δ pathways
• Outcome: HIGH FAO RISK ➔ Direct to Alternative Protocol

Glycolytic Addiction / Wild-Type

• Wild-type APC
• PIK3CA, PTEN, or AKT alterations
• High FDG-PET avidity (SUV ≥ 10)
• Outcome: Favorable ➔ Proceed to Step 3

↓

Step 3: Clinical & Metabolic Safety Screen

Absolute Contraindications

• Severe cachexia (>10% loss)
• Carnitine deficiency
• Severe GI malabsorption
• Outcome: CONTRAINDICATED ➔ Direct to Alternative Protocol

Stable Phenotype

• Preserved muscle mass
• Hyperinsulinemia / Insulin resistance
• Normal lipid processing
• Outcome: APPROVED ➔ Proceed to Optimal Protocol

↓

HIGH-FAT KD CONTRAINDICATED

Alternative Protocol Strategy:

• Fasting-Mimicking Diet (FMD) cycles
• Exogenous Ketone Esters + Low-Fat background diet
• Targeted glycolysis/glutamine inhibition

HIGH-FAT KD APPROVED

Optimal Protocol Strategy:

• Classical Ketogenic Diet or Modified Atkins Diet (MAD)
• Target Glucose-Ketone Index (GKI) < 2.0
• Monitor baseline lipidomics & GKI continuously

---

Detailed Clinical Decision Nodes

Step 1: Anatomic & Tissue Site Assessment

• Red Flag Sites (Skip directly to Alternative Protocol): Primary small intestinal adenocarcinoma, duodenum/jejunum/ileum lesions, or Familial Adenomatous Polyposis (FAP) syndromes.
• Rationale: Direct exposure to high mucosal lipid flux combined with local tissue architecture creates an ideal environment for CPT1A-mediated stem cell proliferation.
• Proceed to Step 2: Brain (GBM), colon, pancreatic, lung, head and neck, or prostate tumors.

Step 2: Genomic & Biomarker Stratification

Evaluate tumor molecular profiling (e.g., NGS panels, transcriptomics, or IHC):

• High FAO Vulnerability (High-Fat KD Contraindicated):
  • APC loss-of-function or truncating mutations.
  • CPT1A amplification or marked overexpression.
  • Upregulated PPARα or PPARδ gene expression signatures.
• High Glycolytic Addiction (High-Fat KD Favorable):
  • PIK3CA activating mutations or PTEN loss (hyper-sensitive to insulin lowering).
  • High baseline ¹⁸F-FDG-PET avidity (standardized uptake value [SUV] ≥ 10).
  • IDH1/2 wild-type glioblastoma profiles.

Step 3: Clinical & Metabolic Safety Screen

Before initiating any restrictive dietary protocol, confirm the patient lacks systemic metabolic red flags:

• Exclusion Criteria: Severe cancer cachexia (involuntary weight loss > 10% over 6 months), active GI malabsorption, primary or secondary carnitine deficiency, or acute pancreatitis.
• Inclusion Criteria: Adequate baseline muscle reserve, presence of insulin resistance or hyperinsulinemia (where lowering IGF-1/insulin yields maximum therapeutic pressure), and preserved hepatic lipid processing.

References:

1. https://www.nature.com/articles/s41586-026-10779-y
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC12966578/